Accidental death from acute selenium poisoning
Author: Tony Lewis
Published online: 7 May 2007
To the Editor: I wish to address a statement made in a recent case report in the Journal entitled Accidental death from acute selenium poisoning.1 The authors claim that the death of a 75-year-old man after ingesting 10 g of sodium selenite “exposes the myth that natural therapies are inherently safe”.
The patient actually purchased sodium selenite powder and tablets. This is a restricted substance and an industrial chemical which would certainly have been labelled a poison.
It should be noted that the maximum recommended daily dose of selenium in complementary medicines in Australia is 52 μg.2 The authors of the case report do point out that the patient took more than 10 000 times the recommended dose of selenium which would be available from a medicine. (My calculations put this closer to 20 000 times.) An individual drinking more than 10 000 times even the daily recommended amount of water would probably not end up in much better shape. Is this evidence of an underlying agenda to discredit natural products?
The Complementary Healthcare Council of Australia recommends that consumers take steps to thoroughly inform themselves about products, preferably by asking their health care practitioner. We also urge them to inform their health care practitioner of which medicines, complementary or otherwise, they are taking.
The incident involving the sodium selenite is regrettable, but for the authors to link the product and this case of fatal ingestion to exposing the myth that natural therapies are safe is, at best, ridiculous, with no foundation.
They also state that adverse reactions to complementary and alternative medicines should be better publicised and more stringently reported to the Adverse Drug Reactions Advisory Committee. Adverse reactions are routinely reported and publicised for all medicines, and have been for some time, as any check of the website of the Therapeutic Goods Administration will show.3,4
I agree with the authors that the case highlights the dangers of consumers’ reliance on the Internet. Local Internet sites that advertise therapeutic goods must conform to the requirements of the Therapeutic Goods Advertising Code, as well as the Therapeutic Goods Act 1989 (Cwlth) and Regulations. However, overseas sites are not necessarily regulated or policed, and may provide inappropriate and misleading information. While our industry’s products are low risk, they should be taken, like other medicines, with due care.
References
- See KA, Lavercombe PS, Dillon J, Ginsberg R. Accidental death from acute selenium poisoning. Med J Aust 2006; 185: 388-389.
- Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Substances that may be used in listed medicines in Australia. 30 Jun 2006. www.tga.gov.au/cm/listsubs.pdf (accessed Mar 2007).
- Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Information for health professionals. Adverse drug reactions: what to report. Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Information for health professionals. Adverse drug reactions: what to report. http://www.tga.gov.au/adr/report.htm (accessed Mar 2007). (accessed Mar 2007).
- Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Guidelines on the reporting of adverse drug reactions by drug sponsors. http://www.tga.gov.au/docs/html/adrguide.htm (accessed Mar 2007).
When ‘Liver Enzymes’ Are Not Hepatic: Late-Onset Pompe Disease
Shauna Madigan, Georgina England, Wayne Rankin
Fatty Liver Disease in Australia: A Narrative Review on the Epidemiology, Natural History, Prognostication and Management in People With Metabolic Dysfunction
Karl Vaz, Daniel Clayton-Chubb, William W. Kemp, Stuart K. Roberts, Ammar Majeed
The early implementation phase of the Omega‐3 Test‐and‐Treat Program for reducing the risk of preterm birth, South Australia, 2021–22: an implementation evaluation study
Karen P Best, Celine Northcott, Lucy A Simmonds, Philippa Middleton, Lisa N Yelland, Vanessa Moffa, Khoa Lam, Penelope Coates, Cornelia Späth, Carol WK Siu, Karen Glover, Rhiannon Smith, Robert Gibson, Maria Makrides
Cause‐specific mortality among Queensland people with cirrhosis, by cirrhosis aetiology and decompensation status, 2007–22: a retrospective cohort study
Vikas Bhasker, Jessica R Fong, Paul J Clark, Gunter F Hartel, Richard Skoien, James O’Beirne, Elizabeth E Powell, Patricia C Valery
The role of GLP‐1 receptor agonists in the management of obesity: risks and opportunities for the Australian health care system
Patrick GM Bolton
The role of GLP‐1 receptor agonists in the management of obesity: risks and opportunities for the Australian health care system
Deshan Sebaratnam, Jessie T Lu, Helen Y Sun